3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
2
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
9
Pancreatic Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Colorectal Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Biliary Tract Neoplasms
4
Stomach Neoplasms
3
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Lymphoma, Follicular
3
Kidney Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Recurrence
2
Oropharyngeal Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Interventions
Gemcitabine
6
Docetaxel
3
durvalumab
2
Mitomycin
2
viscum album peptide
1
tremelimumab
1
pembrolizumab
1
erdafitinib
1
avelumab
1
VPM1002 recombinant BCG vaccine
1
Neoadjuvant Therapy
1
Monatide (IMS 3015)
1
Mitozytrex
1
House Calls
1
Home Care Services
1
Dihematoporphyrin Ether
1
DDMS
1
Cystoscopy
1
Clinical Trials, Phase II as Topic
1
Clinical Trials, Phase I as Topic
1
BCG Vaccine
1
Administration, Intravesical
1
ALT-803
1
ALT-801
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Non-Muscle Invasive Bladder Neoplasms
×
durvalumab
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled
NCT04106115
2024-12-04
DURANCE
University College, London
Phase 1/2
Recruiting
64 enrolled